期刊论文225Ac-DOTATATE dosimetry results from part 1 of the ACTION-1 trial复制

DOI:复制

文献链接: https://jnm.snmjournals.org/content/64/supplement_1/P129/tab-article-info复制

其他信息:

G Sgouros, G Ulaner, T Delie, S Kotiah, D Ferreira…
2023
jnm.snmjournals.org
P129 Introduction: RYZ101 (225 Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting radiopharmaceutical therapy being developed for the treatment of somatostatin receptor 2-expressing (SSTR2 ) solid tumors. ACTION-1 (NCT05477576) is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial comparing treatment with RYZ101 to standard-of-care therapy in patients with inoperable, advanced, SSTR2 , well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following …